Nicholas Vita

Co-Founder of Apriligen, Inc., a cellular gene therapy company dedicated to developing curative treatments for rare, monogenic illnesses. Apriligen's lead candidate, APR-2020, has been granted Orphan Drug and Rare Pediatric Disease designations by the FDA and EMA and is intended to cure one variant of an ultra-rare bone marrow failure syndrome called Diamond Blackfan Anemia. Based on positive pre-clinical results, Apriligen expects to initiate a pivotal Phase I/II clinical trial for APR-2020 soon. The company expects to use its lentiviral platform to develop a pipeline of hematology therapies, all focused on ultra-rare diseases.

Former Member of the Board of Directors, Co-Founder, CEO and first employee of Columbia Care, Inc. Ticker Symbol: CCHW. Served as CEO since company's founding - retired. One of the nation's largest fully-integrated, state-licensed cannabis companies operating throughout the value chain including, pharmacies, dispensaries, home delivery, cultivation and manufacturing. Licensed to operate in Arizona, California, Colorado, Delaware, Florida, Illinois, Maryland, Massachusetts, New Jersey, New York, Ohio, Pennsylvania, Virginia, Washington, D.C., West Virginia, Utah and Missouri. While CEO, Responsible for building the company from concept through IPO and proposed sale. Oversaw company operations and managing the leadership team charged with development and execution of corporate strategy generating over half a billion dollars in revenue annually and involving almost 3,000 colleagues nationwide. Duties included strategy development, allocation and planning decisions and new markets and product development programs in adult use and medical markets. Selected Highlights: - Millions of successful customer interactions annually - Nation's largest patient registry tracking product efficacy, adverse events, dosing and utilization data to support proprietary product development, research trials and studies - Over 93 retail locations (85 active, 8 in development)/dispensaries and 27 cultivation/manufacturing facilities - Among the largest portfolio of branded adult use brands (including award winning Seed & Strain, Triple Seven, Classix, Hedy and Amber) in the most strategically valuable markets

Apelles Investment Management ("AIM") - Healthcare direct investment vehicle (public/private equity and debt) Apelles Public/Private Partnerships Global ("AP-III") - Privatized Military Infrastructure direct investment vehicle (private equity/debt) AIM: Senior Advisor – Co-Founder of Firm. Responsible for providing advice to team that sources, researches, analyzes and manages investments and operating companies with a focus on private equity; mezzanine financings; high yield, bank, distressed and structured credit, and late-stage venture investments in the healthcare sector. Responsible for initial company build-out and oversight of all operations (business, legal, infrastructure) and team of investment and operations professionals. Member of the Management and Investment Committees. AP-III: Senior Advisor. Responsible for providing advice and resources to team that sources, structures and negotiates customized cross-capital structure investments throughout the privatized military infrastructure sectors with specific focus on fixed assets and lodging sub-sectors. Member of the Management and Investment Committees. Board Memberships: Various corporate and not-for-profit entities

Portfolio Manager - Global Healthcare Sector (cross capital structure, emphasis on high yield credit and bank debt) Responsible for sourcing and analyzing investment opportunities and maintaining industry (executive management, mid-level operators and consultants) and governmental (federal, state and local) contacts. Member of Investment Committee (for all industrial sectors). Provided coverage for all healthcare sub-sectors’ public and private investments (long/short) across all asset classes (revolvers, term loans, distressed, HY and IG debt, convertible securities, preferred and common equity). Strategy focused on exploiting cross-capital structure valuation based inefficiencies in highly levered, stressed and distressed credits. Experience with management negotiations/bondholder groups in covenant breach/consent solicitations. Core competencies in enterprise/asset valuation, industry knowledge, capital structure analysis - Part of initial team that saw asset base grow from approximately $35mm to several billion dollars over four year period - Average return on equity during tenure of greater than 20%

Investment Banking Division, Healthcare Department - Analyst, Associate and Vice President. Team leader responsible for structuring, developing and executing transactions across all strategic advisory and financing product lines. Analyzed and implemented strategic alternatives for clients including mergers, acquisitions, leveraged buyouts, spin-offs, raid defenses and restructurings. Evaluated financing alternatives including hybrid, preferred and common equity offerings as well as high yield debt and bank financings. Assisted clients with ratings agency presentations. Developed strong personal relationships with senior management teams throughout healthcare sector in US, Europe and Asia. Provided industry expertise and contacts in support of financial sponsor client teams. Served on transaction teams in North America, Asia and Europe. - Completed over 35 transactions. - Direct Promote from Analyst to Associate Program. Exempted from graduate degree requirement. Selection rate of less than 10% for analyst program worldwide. Consistent top quartile peer reviews.